Menu Search
Equities

Qiagen NV

QIAX:GER

Qiagen NV

Actions
Health CareMedical Equipment and Services
  • Price (EUR)41.05
  • Today's Change0.825 / 2.05%
  • Shares traded456.46k
  • 1 Year change+5.83%
  • Beta0.0678
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Qiagen NV's revenues fell -8.23%from 2.14bn to 1.97bn. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a -19.35% reduction in net income from 423.21m to 341.30m.
Gross margin62.73%
Net profit margin4.73%
Operating margin4.43%
Return on assets1.53%
Return on equity2.57%
Return on investment1.77%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Qiagen NV fell by 62.59m. However, the company earned 459.46m from its operations for a Cash Flow Margin of 23.38%. In addition the company used 87.66m on investing activities and also paid 433.83m in financing cash flows.
Cash flow per share1.35
Price/Cash flow per share31.46
Book value per share15.88
Tangible book value per share3.21
More ▼

Balance sheet in USDView more

Qiagen NV has a Debt to Total Capital ratio of 35.23%, a lower figure than the previous year's 37.43%.
Current ratio2.17
Quick ratio1.89
Total debt/total equity0.5439
Total debt/total capital0.3523
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.